Literature DB >> 22500530

Fecal markers: calprotectin and lactoferrin.

Bincy P Abraham1, Sunanda Kane.   

Abstract

Overall, fecal markers have been found to be more accurate than serum markers. However, fecal markers are not specific for IBD and may be elevated in a range of organic conditions. Fecal calprotectin and lactoferrin can still differentiate inflammatory disease from functional bowel disorders. Comparison studies have found an overall diagnostic accuracy in IBD of 80% to 100% for both calprotectin and lactoferrin. Elevated levels are found in both CD and UC making it difficult to distinguish between these 2 diagnoses from these biomarkers alone. Both markers correlated well to mucosal healing and histologic improvement. Hence, they may be useful in monitoring response to treatment and predicting endoscopic and clinical relapse. Overall, patients with elevated markers were at higher risk of postoperative recurrence than those with normal levels. Fecal markers are useful in predicting pouchitis as well. Fecal markers are helpful as an adjunctive tool in overall evaluation of patients with nonspecific symptoms and as a management tool in those with inflammatory disease to monitor disease activity and possibility of relapse. They are less invasive than colonoscopy and can help guide management in a more cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22500530     DOI: 10.1016/j.gtc.2012.01.007

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  29 in total

1.  Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population.

Authors:  Oriano Radillo; Lorella Pascolo; Stefano Martelossi; Sara Dal Bo; Alessandro Ventura
Journal:  J Clin Lab Anal       Date:  2016-02-15       Impact factor: 2.352

Review 2.  Innate immunity in disease.

Authors:  David E Elliott; Sana S Siddique; Joel V Weinstock
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-12       Impact factor: 11.382

3.  Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease.

Authors:  Phillip Minar; Yael Haberman; Ingrid Jurickova; Ting Wen; Marc E Rothenberg; Mi-Ok Kim; Shehzad A Saeed; Robert N Baldassano; Michael Stephens; James Markowitz; Joel Rosh; Wallace V Crandall; Melvin B Heyman; David R Mack; Anne M Griffiths; Susan S Baker; Jeffrey S Hyams; Subra Kugathasan; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

4.  Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease.

Authors:  Phillip Minar; Kimberly Jackson; Yi-Ting Tsai; Heidi Sucharew; Michael J Rosen; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

Review 5.  Gastrointestinal motility disorders in inflammatory bowel diseases.

Authors:  Gabrio Bassotti; Elisabetta Antonelli; Vincenzo Villanacci; Marianna Salemme; Manuela Coppola; Vito Annese
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 6.  Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review.

Authors:  Travis Murdoch; Sarah O'Donnell; Mark S Silverberg; Remo Panaccione
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

Review 7.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 8.  Host response to Clostridium difficile infection: Diagnostics and detection.

Authors:  Elena A Usacheva; Jian-P Jin; Lance R Peterson
Journal:  J Glob Antimicrob Resist       Date:  2016-09-20       Impact factor: 4.035

9.  The Efficacy of Probiotic (Lactobacillus rhamnosus GG) and 5-ASA (Aminosalicylic Acid) in the Treatment of Experimental Radiation Proctitis in Rats.

Authors:  Özgür Dandin; Mehmet Levhi Akin; Ahmet Ziya Balta; Ergün Yücel; Dursun Özgür Karakaş; Sezai Demirbaş; Sevim Özdemir; Apdullah Haholu
Journal:  Indian J Surg       Date:  2013-05-05       Impact factor: 0.656

Review 10.  Faecal calprotectin: Management in inflammatory bowel disease.

Authors:  José Manuel Benítez; Valle García-Sánchez
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.